Metabolic dysfunction-associated fatty liver disease is a ubiquitous latent cofactor in viral- and alcoholic-related hepatocellular carcinoma: Editorial on “Global prevalence of metabolic dysfunction-associated fatty liver disease-related hepatocellular carcinoma: A systematic review and meta-analysis”

키워드

참고문헌 (20)

1. Eslam M, "A new definition for metabolic dysfunction-associated fatty liver disease : An international expert consensus statement", J Hepatol, 73, pp.202~209 (2020)
2. Kawaguchi T, "MAFLD enhances clinical practice for liver disease in the Asia-Pacific region", Clin Mol Hepatol, 28, pp.150~163 (2022)
3. Kawaguchi T, "MAFLD : Renovation of clinical practice and disease awareness of fatty liver", Hepatol Res, 52, pp.422~432 (2022)
4. Fukunaga S, "Lean", normal-weight metabolic dysfunctionassociated fatty liver disease is a risk factor for reflux esophagitis, 2022, pp.52, 699~711
5. Fukunaga S, "Impact of non-obese metabolic dysfunctionassociated fatty liver disease on risk factors for the recurrence of esophageal squamous cell carcinoma treated with endoscopic submucosal dissection : A multicenter study", Hepatol Res, 54, pp.201~212 (2024)
6. Crane H, "Global prevalence of metabolic dysfunctionassociated fatty liver disease-related hepatocellular carcinoma : A systematic review and meta-analysis", Clin Mol Hepatol, 30, pp.436~448 (2024)
7. Crane H, "MAFLD : an optimal framework for understanding liver cancer phenotypes", J Gastroenterol, 58, pp.947~964 (2023)
8. Llovet JM, "Nonalcoholic steatohepatitisrelated hepatocellular carcinoma : pathogenesis and treatment", Nat Rev Gastroenterol Hepatol, 20, pp.487~503 (2023)
9. Yamamura S, "MAFLD identifies patients with significant hepatic fibrosis better than NAFLD", Liver Int, 40, pp.3018~3030 (2020)
10. Wang Z, "Serum fibrosis tests guide prognosis in metabolic dysfunction-associated fatty liver disease patients referred from primary care", Clin Gastroenterol Hepatol, 20, pp.2041~2049 (2022)
11. Kawaguchi T, "Leaky gut-derived tumor necrosis factor-α causes sarcopenia in patients with liver cirrhosis", Clin Mol Hepatol, 28, pp.177~180 (2022)
12. Chun HS, "Risk stratification using sarcopenia status among subjects with metabolic dysfunction-associated fatty liver disease", J Cachexia Sarcopenia Muscle, 12, pp.1168~1178 (2021)
13. Kim HK, "Association of visceral fat obesity, sarcopenia, and myosteatosis with non-alcoholic fatty liver disease without obesity", Clin Mol Hepatol, 29, pp.987~1001 (2023)
14. Eslam M, "Toward more accurate nomenclature for fatty liver diseases", Gastroenterology, 157, pp.590~593 (2019)
15. Chang Y, "Nonheavy drinking and worsening of noninvasive fibrosis markers in nonalcoholic fatty liver disease : A cohort study", Hepatology, 69, pp.64~75 (2019)
16. Kawamura Y, "Effects of alcohol consumption on hepatocarcinogenesis in Japanese patients with fatty liver disease", Clin Gastroenterol Hepatol, 14, pp.597~605 (2016)
17. Tabrizian P, "Immunotherapy and transplantation for hepatocellular carcinoma", J Hepatol, 80, pp.822~825 (2024)
18. Finn RS, "Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma", N Engl J Med, 382, pp.1894~1905 (2020)
19. Abou-Alfa GK, "Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma", NEJM Evid, 1, pp.EVIDoa2100070~ (2022)
20. Shimose S, "The beneficial impact of metabolic dysfunction-associated fatty liver disease on lenvatinib treatment in patients with non-viral hepatocellular carcinoma", Hepatol Res, 53, pp.104~115 (2023)

관련 논문AI추천